Agios Pharmaceuticals, Inc. (AGIO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
88 Sidney Street
Cambridge, MA 02139-4169
United States of America (the)
Phone
617 649 8600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
486
First IPO Date
July 24, 2013
| Name | Title | Pay | Year Born |
| Brian Goff | Chief Executive Officer & Director | 1.45M | 1969 |
| Craig Thompson | Co-Founder | 50,000 | 1953 |
| Tak Wah Mak FRSC | Co-Founder | 50,000 | 1946 |
| Shin-San Su | Co-Founder | 50,000 | 1956 |
| Lewis Clayton Cantley | Co-Founder | 50,000 | 1949 |
| James William Burns | Chief Legal Officer | 780,510 | 1978 |
| Cecilia Jones | Chief Financial Officer | 791,835 | 1975 |
| Tsveta Milanova | Chief Commercial Officer | 836,643 | 1978 |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 887,232 | 1980 |
| Krishnan Viswanadhan | Chief Strategy & Operations Officer | 931,509 | 1979 |
| Steven Vickers | Vice President of Sales | 0 | N/A |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer | 0 | 1982 |
| Clive Patience | Chief Technical Operations Officer | 0 | 1964 |
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.